Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7485302 Treatment with anti-ErbB2 antibodies and chemotherapeutic agents

Patent 7485302 was granted and assigned to Genentech on February, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Leonard G. Presta0

Mark Sliwkowski0

Camellia W. Adams0

Date of Patent

February 3, 2009

0

Patent Application Number

114290430

Date Filed

May 5, 2006

0

Patent Citations Received

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 11654105 Subcutaneous HER2 antibody formulations

0

US Patent 11655305 Treatment of metastatic breast cancer

0

US Patent 11713358 Chimeric polypeptide assembly and methods of making and using the same

0

US Patent 11981744 Chimeric polypeptide assembly and methods of making and using the same

0

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

0

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

0

Patent Primary Examiner

Alana M. Harris

0

Patent abstract

The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7485302 Treatment with anti-ErbB2 antibodies and chemotherapeutic agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool